Xenogen ivis 200

Manufactured by PerkinElmer

Sourced in United States

The Xenogen IVIS 200 is a bioluminescence and fluorescence imaging system designed for in vivo and ex vivo optical imaging applications. It features a sensitive CCD camera and automated stage for capturing high-resolution images of luminescent and fluorescent samples.

Automatically generated - may contain errors

Lab products found in correlation

Living image software, by PerkinElmer (6 mentions) D luciferin, by PerkinElmer (4 mentions) Beetle luciferin, by Promega (3 mentions) Luciferin substrate, by PerkinElmer (2 mentions) Carbon tetrachloride ccl4, by Merck Group (2 mentions) Living image, by PerkinElmer (2 mentions) Living image 3, by PerkinElmer (2 mentions) Phosphate buffered saline (pbs), by Corning (1 mentions) Polyinosinic polycytidylic acid polyic, by GE Healthcare (1 mentions) D luciferin, by GoldBio (1 mentions) Ifn α, by R&D Systems (1 mentions) Balb c mice, by Janvier Labs (1 mentions) Prism 7, by GraphPad (1 mentions) Xenolight d luciferin, by PerkinElmer (1 mentions) Ax70 microscope, by Olympus (1 mentions) X rad smart, by Precision X-Ray (1 mentions) Living image 4, by PerkinElmer (1 mentions) Bradford assay, by Bio-Rad (1 mentions) Bgj 398, by Chemietek (1 mentions) Dmso d6, by Agilent Technologies (1 mentions)

Spelling variants of this product

IVIS 200 (61 citations) Xenogen IVIS 200 Imaging System (32 citations) Xenogen IVIS (22 citations) Xenogen IVIS-200 System (13 citations) Xenogen-IVIS 200 in vivo Imaging System (7 citations) Xenogen IVIS Imaging system 200 series (3 citations) Xenogen IVIS-200 Spectrum camera (3 citations) Xenogen IVIS 200 Biophotonic Imager (2 citations) Xenogen IVIS 200 in vivo fluorescence system (2 citations)

43 protocols using xenogen ivis 200

Encapsulated HEK-293 Cell Survival in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

A HEK-293 (Luc-2) cell pellet, at a density of 1 × 10⁷ cell/ml, was combined with 6 ml of 1.2% sodium alginate
solution, and standardized process parameters were used for the encapsulation of the cells.
ICR male mice (NaraBiotec), 8–10 weeks old with a body weight of 16–20 g, were used for this experiment. The control group and test groups were injected with 1
ml of 1 × 10⁷ non-encapsulated or encapsulated HEK-293T (Luc-2) cells, respectively. The survival rates of the encapsulated
HEK-293 (Luc-2) cells were then compared to those of the non-encapsulated HEK-293T (Luc-2) cells. In vivo bioluminescent imaging was performed
immediately after injection, and 1 d, 3 d and 7 d post-injection, using a Xenogen IVIS 200 (Xenogen IVIS 200, PerkinElmer, Waltham, MA, U.S.A.) in Chuncheon
Center of Korea Basic Science Institute. The animals were injected with 100 µl of D-lucferin (D-lucferin, PerkinElmer) intraperitoneally 15 min
before imaging.

KOH E., JUNG Y.C., WOO H.M, & KANG B.J. (2017). Injectable alginate-microencapsulated canine adipose tissue-derived mesenchymal stem cells for enhanced viable cell retention. The Journal of Veterinary Medical Science, 79(3), 492-501.

+ Open protocol

+ Expand

Modeling Melanoma Tumor Growth and Metastasis in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

Experimental protocols were approved by the IACUC of the Icahn School of Medicine at Mount Sinai and New York University. Six-week-old male C57BL/6J mice and 6-week-old female NOD/SCID/IL2γR^−/− mice (The Jackson Laboratory, catalog 05557) were used for in vivo studies. To study tumor growth, 1 × 10⁶ YUMMER1.7 murine melanoma cells were injected s.c. into the flanks of each C57BL/6J mouse. Tumor volumes were calculated using the following equation: 0.5 × l × w². To examine lung metastasis, 1.5 × 10⁵ SKmel147 human melanoma cells were i.v. injected into the lateral tail vein of each NOD/SCID/IL2γR^−/− mouse. For the analysis of liver metastasis, 5 × 10⁴ SKmel147 human melanoma cells were delivered into each NOD/SCID/IL2γR^−/− mouse by intracardiac injection. Bioluminescence imaging was performed using the Xenogen IVIS 200 (Perkin-Elmer) once per week until the experimental end point. Images were quantified using Living Image software. The mice were anesthetized with 2.5% isoflurane prior to imaging and then injected with 150 mg/kg D-luciferin i.p. (Perkin-Elmer). Exposure time was adjusted to avoid pixel saturation. A total bioluminescence flux (photons/second) was calculated for each region of interest (ROI).

Mendelson K., Martin T.C., Nguyen C.B., Hsu M., Xu J., Lang C., Dummer R., Saenger Y., Messina J.L., Sondak V.K., Desman G., Hasson D., Bernstein E., Parsons R.E, & Celebi J.T. (2024). Differential histone acetylation and super-enhancer regulation underlie melanoma cell dedifferentiation. JCI Insight, 9(6), e166611.

+ Open protocol

+ Expand

In vivo HDL Tracking in Rabbits

Check if the same lab product or an alternative is used in the 5 most similar protocols

At 24 h before sacrifice, all rabbits received fluorescently labeled (DiD) high-density lipoprotein (HDL) (~1 mg dye/rabbit) in 5-ml phosphate-buffered saline solution via the marginal ear vein. After sacrifice, all aortas, both thoracic and abdominal, were placed on thick black paper and imaged with a Xenogen IVIS-200 optical imaging system (Perkin Elmer, Waltham, Massachusetts). Fluorescence images were acquired with excitation and emission wavelengths of 680 and 720 nm and a field of view of 6.5 and 22.8 cm using different exposure times.

Senders M.L., Que X., Cho Y.S., Yeang C., Groenen H., Fay F., Calcagno C., Meerwaldt A.E., Green S., Miu P., Lobatto M.E., Reiner T., Fayad Z.A., Witztum J.L., Mulder W.J., Pérez-Medina C, & Tsimikas S. (2018). PET/MR Imaging of Malondialdehyde-Acetaldehyde Epitopes With a Human Antibody Detects Clinically Relevant Atherothrombosis. Journal of the American College of Cardiology, 71(3), 321-335.

+ Open protocol

+ Expand

In Vivo Imaging of Tumor Xenografts

Check if the same lab product or an alternative is used in the 5 most similar protocols

An A431-bearing mouse was injected with ¹²⁵I-Cetuximab anaesthetized by inhalation of 1.5% Isoflurane and oxygen and imaged at several time-points post injection using a gamma camera. B16F10 luc2+-bearing mice were anaesthetized by inhalation of 1.5% Isoflurane and oxygen. 3 mg luciferine were injected intraperitoneally per mouse. The plateau phase of luciferase activity was established prior (data not shown). For the following experiments animals (n:3-6) were imaged 8 min. after injection using a Xenogen iVis 200 bioluminescence imager (PerkinElmer, Waltham, Massachussetts, U.S.A.).

Melzig C., Golestaneh A.F., Mier W., Schwager C., Das S., Schlegel J., Lasitschka F., Kauczor H.U., Debus J., Haberkorn U, & Abdollahi A. (2018). Combined external beam radiotherapy with carbon ions and tumor targeting endoradiotherapy. Oncotarget, 9(52), 29985-30004.

+ Open protocol

+ Expand

In Vivo Bioluminescence Imaging

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mice were imaged on the Xenogen IVIS 200 (Perkin Elmer, Waltham, MA) approximately five minutes after injection with 100 μg of luciferin substrate (Perkin Elmer, Waltham, MA) in phosphate buffered saline without calcium or magnesium (PBS; Corning, Manassas, VA) as previously described19 (link).

Woodard L.E., Cheng J., Welch R.C., Williams F.M., Luo W., Gewin L.S, & Wilson M.H. (2017). Kidney-specific transposon-mediated gene transfer in vivo. Scientific Reports, 7, 44904.

+ Open protocol

+ Expand

Hoxa Locus Deletion Across Models

Check if the same lab product or an alternative is used in the 5 most similar protocols

In vitro deletion of the Hoxa locus was by IFNα (R&D Systems, Abingdon, UK) treatment at the indicated dose and time. In vivo deletion in MAFF-MA9 leukemic mice was achieved by intraperitoneal (IP) injection of Polyinosinic:polycytidylic acid (Poly I:C; GE Healthcare Life Sciences, Buckinghamshire, UK) as previously described [46 (link)]. Briefly, mice were given 10 µg/g Poly I:C or vehicle (PBS) up to a maximum of 250 µg/mouse. Ex vivo deletion was by direct exposure to MSCV-Cre-GFP or MSCV-GFP control retroviral supernatants followed by cell sorting and gene expression profiling. Mice transplanted with traceable (pSLIEW) leukemias were injected IP with 150 mg D-luciferin/kg (Gold Biotechnology, St. Louis, MO, USA) and imaged using the Xenogen IVIS 200 (PerkinElmer, Buckinghamshire, UK). Nested PCR was used to identify individual colony bands.

Kettyle L.M., Lebert-Ghali C.É., Grishagin I.V., Dickson G.J., O’Reilly P.G., Simpson D.A., Bijl J.J., Mills K.I., Sauvageau G, & Thompson A. (2019). Pathways, Processes, and Candidate Drugs Associated with a Hoxa Cluster-Dependency Model of Leukemia. Cancers, 11(12), 2036.

+ Open protocol

+ Expand

Evaluating antivirals against influenza in mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

Female BALB/c mice (4–6 weeks old) were purchased from Charles River Laboratory Animal Technology (Beijing, China) and maintained under specific pathogen-free conditions. All efforts were made to minimize any suffering and the number of animals.
For mouse infections, mice were intranasally inoculated under isoflurane anesthesia with the recombinant influenza PR8-Fluc virus at a dose of 1000 TCID₅₀. At day 2 p.i., bioluminescence imaging was performed as previously described (Lin et al., 2023 (link)). In brief, mice were anaesthetized and intraperitoneally administered with the substrate D-luciferin at 150 mg/kg, and then subjected to image acquisition using the Xenogen IVIS 200 (PerkinElmer, Waltham, USA) after 10 min. The images were analyzed using the Living Image software (version 4.4).
For antiviral determination, groups of mice (n = 3) were separately treated with ALLO (40 mg/kg/day), the vehicle only (PBS) as negative control, and oseltamivir phosphate (30 mg/kg/day) as positive control. All treatment was given intraperitoneally twice a day, starting at 2 h before virus inoculation.

Dong M., Wang Y., Li P., Chen Z., Anirudhan V., Cui Q., Rong L, & Du R. (2023). Allopregnanolone targets nucleoprotein as a novel influenza virus inhibitor. Virologica Sinica, 38(6), 931-939.

+ Open protocol

+ Expand

Evaluating Thawed and Fresh LNP-Encapsulated repLuc

Check if the same lab product or an alternative is used in the 5 most similar protocols

To qualitatively assess the efficacy of thawed LNPs compared with freshly prepared samples using repRNA encoding for luciferase (repLuc) as a reporter, we simulated vaccination in cohorts of Balb/C mice by intramuscularly (i.m.) injecting 1 μg RNA doses of the LNPs loaded with repLuc in each of the left and right gastrocnemius muscle. At days 1, 3, 7, 10, and 15 post-i.m. injection, the mice were intraperitoneally (i.p.) administered 200 μL of luciferin (50 mg/mL in PBS), and imaged using the In Vivo Imaging System (Xenogen IVIS 200; PerkinElmer) 10 min post-i.p. injection.

Kim B., Hosn R.R., Remba T., Yun D., Li N., Abraham W., Melo M.B., Cortes M., Li B., Zhang Y., Dong Y, & Irvine D.J. (2022). Optimization of storage conditions for lipid nanoparticle-formulated self-replicating RNA vaccines. Journal of Controlled Release, 353, 241-253.

+ Open protocol

+ Expand

Biodistribution of BCN-Cy5.5 in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

All animal studies were conducted in accordance with the University of Washington (UW) Institute of Animal Care and Use Committee (IACUC) approved protocols as well as with federal guidelines. Five-week-old female BALB/c mice were purchased from The Jackson Laboratory (Bar Harbor, Maine) and housed in the animal research facility at UW. Mice were intravenously injected with BCN-Cy5.5 (1 mg/mL, 200 μL) and were euthanized 4, 24, 48, or 72 h after injection. Organs (heart, lungs, liver, spleen, kidneys) were collected and fluorescence intensities from these organs were measured by a XENOGEN IVIS 200 imaging system (PerkinElmer Inc.). An excitation wavelength of 710 nm and an ICG emission filter were used.

Mu Q., Wang H., Gu X., Stephen Z.R., Yen C., Chang F.C., Dayringer C.J, & Zhang M. (2019). Biconcave Carbon Nanodisk for Enhanced Drug Accumulation and Chemo-photothermal Tumor Therapy. Advanced healthcare materials, 8(8), e1801505.

+ Open protocol

+ Expand

Tracking Stem Cells in Urethral Repair

Check if the same lab product or an alternative is used in the 5 most similar protocols

To track hMSC after local periurethral injection in vivo in real time, and to prove cell viability, we transfected hMSCs with a triple-fusion imaging reporter system [17 (link)] selected primarily for its luciferase expression, which enables in vivo BLI to assess hMSC viability and distribution. Seven rats underwent VD and received 1–1.5 million luciferase-expressing hMSCs periurethrally through a vaginal approach immediately after VD. Three control rats also received local periurethral injection of 1.5 million luciferase-expressing hMSCs but did not undergo VD.
For BLI, rats were first anesthetized with isoflurane gas 2 h after hMSCs injection and then given a single injection containing 0.8 ml of 50 mg/ml d-luciferin potassium salt dissolved in phosphate-buffered saline (PBS). Ten min after luciferin injection, the rats were imaged on a Xenogen IVIS 200 bioluminescence scanner (PerkinElmer). Images were collected for 30 s, 1 min, 3 min, and 10 min to improve detectability of stem cells. BLI data was obtained immediately following hMSC inoculation and at days 1 and 2 following inoculation. Animals were sacrificed 7 days after hMSC injection, and the urethra was dissected out and underwent human Alu genomic repeat staining to confirm BLI results histopathologically.

Sadeghi Z., Isariyawongse J., Kavran M., Izgi K., Marini G., Molter J., Daneshgari F., Flask C.A., Caplan A, & Hijaz A. (2015). Mesenchymal stem cell therapy in a rat model of birth-trauma injury: functional improvements and biodistribution. International urogynecology journal, 27(2), 291-300.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!